Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 13701
Country/Region: Kenya
Year: 2012
Main Partner: Kenya Medical Supplies Agency
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: USAID
Total Funding: $4,000,000

Kenya Medical Supplies Agency (KEMSA) is a customer-focused integrated medical logistics provider for all public health facilities in Kenya. As a State Corporation, KEMSA is a secure source of value-for-money drugs and other medical supplies to over 5,000 facilities. KEMSA has also received substantial TA and support from USAID in human resource capacity building through the deployment of key advisors in areas of business development, procurement, IT and supply chain management. With USAID support, KEMSA has invested in an effective Enterprise Resource Planning (ERP) system that has led to the full automation and integration of KEMSA operations and overall business processes, resulting in greater efficiency and improved service delivery. KEMSA's fully automated central warehouse in Nairobi is now functioning under the platform of a Warehouse Module System hosted by the ERP. This has significantly improved efficiency in inventory management and processing of health facilities requirements. KEMSA has successfully implemented the Framework Contract system, and all current procurements are aligned to KEMSAs strategic and business plan with enhanced visibility of all health care commodities in the supply chain. Currently KEMSA has a total allocation of KES 5.3 Billion ($60m) for essential medical supplies, approximately KES7.0 billion ($85m) for programs such as HIV, malaria and tuberculosis. KEMSA has been appointed as the procurement agent for the GFATM R10 procurements, and the USG is confident that KEMSA is ready to start handling some PEPFAR commodities. This is a new award, and no vehicle procurement is planned. This activity supports GHI/LLC and is funded primarily with pipeline funds in this budget cycle.

Global Fund / Programmatic Engagement Questions

1. Is the Prime Partner of this mechanism also a Global Fund principal or sub-recipient, and/or does this mechanism support Global Fund grant implementation? Yes2. Is this partner also a Global Fund principal or sub-recipient? Neither3. What activities does this partner undertake to support global fund implementation or governance?

Budget Code Recipient(s) of Support Approximate Budget Brief Description of ActivitiesHTXS 0 Procurement of commodities.

Funding for Care: Adult Care and Support (HBHC): $0

KEMSA will procure basic care kits (BCK) for provision to implementing care and support programs within Kenya. Kemsa will procure the various items of the BCK, pack, warehouse and distribute to the various facilities. KEMSA supplies commodities to the whole country through direct distribution. The commodity aspects of the programs are continually monitored and evaluated using data collected from regular monthly facility-level patient, stock, and distribution reports; internal distribution records from KEMSA; and direct customer feedback from partners and service providers.

Funding for Care: TB/HIV (HVTB): $0

KEMSA will procure reagents, equipments and consumables to support the national TB program. Availiability of screening and protective materials is necessary for the achievement of the five Is for the TB program. Therefore KEMSA will liaise with NASCOP, the national TB program and the USG to ensure that propoer selection, quantification and procurement of the various TB commodities.

Funding for Laboratory Infrastructure (HLAB): $0

KEMSA procures lab reagents, equipments and accessaries on behalf of GOK. Under the KEMSA fixed-amount remimbursable agreement (FARA), KEMSA will procure laboratory equipment, reagents and consumables for the national HIV program. KEMSA participates as an active member of the Commodity Security Committee (coordinated by NASCOP, the Kenyan HIV/AIDS coordinating body) and participates in national quantification and procurement planning exercises. KEMSA will warehouse and distribute the lab reagents and consumables. KEMSA will coordinates with both NASCOP and USG team to ensure proper allocation of the various commodities to the health facilities.

Funding for Biomedical Prevention: Blood Safety (HMBL): $0

KEMSA will procure equipment and supplies necessary for safe processing, storage and transport of blood and blood products at the blood banks and hospitals. Appropriate blood bags or pediatric and component preparation will be procured.

Funding for Biomedical Prevention: Injection Safety (HMIN): $0

KEMSA will procure equipment and supplies necessary for safe injection, phlebotomy and other blood drawing procedures and medical waste disposal commodities: safety boxes for disposal of medical sharps, color coded waste disposal bins, bags and transfer trolleys, safety lancets, safe lock needles, blood and Intravenous fluid giving sets as well as open and closed phlebotomy systems will be procured. These will facilitate safe injection practice, segregation of health care waste and its appropriate disposal. These supplies will be distributed to health facilities through various partners in the Kenya Injection safety program.

Funding for Prevention: HIV Testing and Counseling (HVCT): $4,000,000

KEMSA will procure HIV rapid test kits for the national program. KEMSA will liaise with NASCOP, USG and other stakeholders in quantifying the required amounts of test kits. Kemsa will procure screening, confirmatory and tie breaker test kits as per the national testing protocol. KEMSA will ware and distribute the test kits based on reports received from the testing facilities. Care will be taken to ensure continuous availability of test kits.

Funding for Treatment: ARV Drugs (HTXD): $0

KEMSA will distribute ARVs procured by the USG to the various ART facilities allocated to KEMSA by NASCOP. KEMSA participates as an active member of the Commodity Security Committee (coordinated by NASCOP, the Kenyan HIV/AIDS coordinating body) and participates in national quantification and procurement planning exercises. In 2011 NASCOP divided the ART facilities into two as a way of eliminating double reporting and facilities receiving commodities from two warehouses. There have been no stockouts of ARVs as commodities shared across the two pipelines. KEMSA actively monitors stocks at all levels of the supply chain and coordinates among other members of the supply chain and among implementing partners to avoid future stockouts.

Funding for Treatment: Adult Treatment (HTXS): $0

KEMSA will procure, warehouse and distribute commodities like CD4 and viral reagents to support HIV treatment services.

Funding for Treatment: Pediatric Treatment (PDTX): $0

KEMSA will procure various commodities to support the pediatric treatment services. KEMSA will liaise with NASCOP and USG in selection and quantification of the various commodities required for provision of pediatric services. KEMSA will warehouse and distribute these commodities all facilities offering pediatric ART services.